196 related articles for article (PubMed ID: 12930602)
1. The role of radioactive iodine in the treatment of Hürthle cell carcinoma of the thyroid.
Besic N; Vidergar-Kralj B; Frkovic-Grazio S; Movrin-Stanovnik T; Auersperg M
Thyroid; 2003 Jun; 13(6):577-84. PubMed ID: 12930602
[TBL] [Abstract][Full Text] [Related]
2. Hürthle cell carcinoma: a clinicopathological study of thirteen cases.
Ozlem Küçük N; Kulak H; Tokmak E; Tar P; Ibiş E; Aras G
Nucl Med Commun; 2006 Apr; 27(4):377-9. PubMed ID: 16531925
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes following empiric radioiodine therapy in patients with structurally identifiable metastatic follicular cell-derived thyroid carcinoma with negative diagnostic but positive post-therapy 131I whole-body scans.
Sabra MM; Grewal RK; Tala H; Larson SM; Tuttle RM
Thyroid; 2012 Sep; 22(9):877-83. PubMed ID: 22827641
[TBL] [Abstract][Full Text] [Related]
4. Lack of impact of radioiodine therapy in tg-positive, diagnostic whole-body scan-negative patients with follicular cell-derived thyroid cancer.
Fatourechi V; Hay ID; Javedan H; Wiseman GA; Mullan BP; Gorman CA
J Clin Endocrinol Metab; 2002 Apr; 87(4):1521-6. PubMed ID: 11932275
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcome of patients with papillary thyroid carcinoma who have recurrence after initial radioactive iodine therapy.
Vassilopoulou-Sellin R; Schultz PN; Haynie TP
Cancer; 1996 Aug; 78(3):493-501. PubMed ID: 8697396
[TBL] [Abstract][Full Text] [Related]
6. Oncocytic Papillary Thyroid Carcinoma and Oncocytic Poorly Differentiated Thyroid Carcinoma: Clinical Features, Uptake, and Response to Radioactive Iodine Therapy, and Outcome.
Lukovic J; Petrovic I; Liu Z; Armstrong SM; Brierley JD; Tsang R; Pasternak JD; Gomez-Hernandez K; Liu A; Asa SL; Mete O
Front Endocrinol (Lausanne); 2021; 12():795184. PubMed ID: 34975765
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological features and outcomes after radioactive iodine treatment of oncocytic well-differentiated thyroid carcinomas.
Amouri W; Charfeddine S; Charfi S; Jardak I; Boudawara T; Guermazi F
Nucl Med Commun; 2019 Sep; 40(9):888-893. PubMed ID: 31343615
[TBL] [Abstract][Full Text] [Related]
8. Impact of Patient Age and Histological Type on Radioactive Iodine Avidity of Recurrent Lesions of Differentiated Thyroid Carcinoma.
Nakanishi K; Kikumori T; Miyajima N; Takano Y; Noda S; Takeuchi D; Iwano S; Kodera Y
Clin Nucl Med; 2018 Jul; 43(7):482-485. PubMed ID: 29688947
[TBL] [Abstract][Full Text] [Related]
9. Radioactive iodine ablation does not prevent recurrences in patients with papillary thyroid microcarcinoma.
Kim HJ; Kim NK; Choi JH; Kim SW; Jin SM; Suh S; Bae JC; Min YK; Chung JH; Kim SW
Clin Endocrinol (Oxf); 2013 Apr; 78(4):614-20. PubMed ID: 22957654
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors in patients with Hürthle cell neoplasms of the thyroid.
Lopez-Penabad L; Chiu AC; Hoff AO; Schultz P; Gaztambide S; Ordoñez NG; Sherman SI
Cancer; 2003 Mar; 97(5):1186-94. PubMed ID: 12599224
[TBL] [Abstract][Full Text] [Related]
11. The effectiveness of radioactive iodine for treatment of low-risk thyroid cancer: a systematic analysis of the peer-reviewed literature from 1966 to April 2008.
Sacks W; Fung CH; Chang JT; Waxman A; Braunstein GD
Thyroid; 2010 Nov; 20(11):1235-45. PubMed ID: 21062195
[TBL] [Abstract][Full Text] [Related]
12. Treatment and outcome of 32 patients with distant metastases of Hürthle cell thyroid carcinoma: a single-institution experience.
Besic N; Schwarzbartl-Pevec A; Vidergar-Kralj B; Crnic T; Gazic B; Marolt Music M
BMC Cancer; 2016 Feb; 16():162. PubMed ID: 26921186
[TBL] [Abstract][Full Text] [Related]
13. Timing of Radioactive Iodine Administration Does Not Influence Outcomes in Patients with Differentiated Thyroid Carcinoma.
Scheffel RS; Zanella AB; Dora JM; Maia AL
Thyroid; 2016 Nov; 26(11):1623-1629. PubMed ID: 27549175
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcomes following low-dose radioiodide ablation for differentiated thyroid cancer.
Welsh L; Powell C; Pratt B; Harrington K; Nutting C; Harmer C; Newbold K
J Clin Endocrinol Metab; 2013 May; 98(5):1819-25. PubMed ID: 23493434
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant chemotherapy in 29 patients with locally advanced follicular or Hürthle cell thyroid carcinoma: a phase 2 study.
Besic N; Auersperg M; Gazic B; Dremelj M; Zagar I
Thyroid; 2012 Feb; 22(2):131-7. PubMed ID: 22175241
[TBL] [Abstract][Full Text] [Related]
16. Radioactive Iodine Treatment Is Associated with Improved Survival for Patients with Hürthle Cell Carcinoma.
Jillard CL; Youngwirth L; Scheri RP; Roman S; Sosa JA
Thyroid; 2016 Jul; 26(7):959-64. PubMed ID: 27150319
[TBL] [Abstract][Full Text] [Related]
17. Graves disease and metastatic hormonal-active Hürthle cell thyroid cancer: A case report.
Besic N; Vidergar-Kralj B; Zaletel K; Grasic-Kuhar C
Medicine (Baltimore); 2021 Jun; 100(25):e26384. PubMed ID: 34160415
[TBL] [Abstract][Full Text] [Related]
18. Radioactive iodine offers survival improvement in patients with follicular carcinoma of the thyroid.
Podnos YD; Smith D; Wagman LD; Ellenhorn JD
Surgery; 2005 Dec; 138(6):1072-6; discussion 1076-7. PubMed ID: 16360393
[TBL] [Abstract][Full Text] [Related]
19. Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer.
Tuttle RM; Leboeuf R; Robbins RJ; Qualey R; Pentlow K; Larson SM; Chan CY
J Nucl Med; 2006 Oct; 47(10):1587-91. PubMed ID: 17015892
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Empiric Versus Whole-Body/-Blood Clearance Dosimetry-Based Approach to Radioactive Iodine Treatment in Patients with Metastases from Differentiated Thyroid Cancer.
Deandreis D; Rubino C; Tala H; Leboulleux S; Terroir M; Baudin E; Larson S; Fagin JA; Schlumberger M; Tuttle RM
J Nucl Med; 2017 May; 58(5):717-722. PubMed ID: 27738010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
